A D R Huitema
Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy
Jörger M, Beijnen J, Cerny T, Meulendijks D, Zueger M, Meijerman I, Rosing H, Vainchtein L, Smits P, Doodeman V, Cats A, Boot H, Huitema A, Schellens J. Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy. Cancer Chemother Pharmacol 2015; 75:763-72.
Feb 13, 2015Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy
Feb 13, 2015Cancer Chemother Pharmacol 2015; 75:763-72
Jörger Markus, Beijnen J H, Cerny Thomas, Meulendijks D, Zueger M, Meijerman I, Rosing H, Vainchtein L, Smits P H M, Doodeman V D, Cats A, Boot H, Huitema A D R, Schellens J H M
Safety and pharmacology of gemcitabine and capecitabine in patients with advanced pancreatico-biliary cancer and hepatic dysfunction
Jörger M, Huitema A, Koeberle D, Rosing H, Beijnen J, Hitz F, Cerny T, Schellens J, Gillessen Sommer S. Safety and pharmacology of gemcitabine and capecitabine in patients with advanced pancreatico-biliary cancer and hepatic dysfunction. Cancer Chemother Pharmacol 2013; 73:113-24.
Oct 29, 2013Safety and pharmacology of gemcitabine and capecitabine in patients with advanced pancreatico-biliary cancer and hepatic dysfunction
Oct 29, 2013Cancer Chemother Pharmacol 2013; 73:113-24
Jörger Markus, Huitema A D R, Koeberle D, Rosing H, Beijnen J H, Hitz Felicitas, Cerny Thomas, Schellens J H M, Gillessen Sommer Silke
Rational administration schedule for high-dose methotrexate in patients with primary central nervous system lymphoma
Jörger M, Huitema A, Illerhaus G, Ferreri A. Rational administration schedule for high-dose methotrexate in patients with primary central nervous system lymphoma. Leuk Lymphoma 2012; 53:1867-75.
May 21, 2012Rational administration schedule for high-dose methotrexate in patients with primary central nervous system lymphoma
May 21, 2012Leuk Lymphoma 2012; 53:1867-75
Jörger Markus, Huitema A D R, Illerhaus G, Ferreri A J M
High-dose methotrexate in patients with primary central nervous system lymphoma: does drug exposure really matter?
Jörger M, Huitema A, Illerhaus G, Ferreri A. High-dose methotrexate in patients with primary central nervous system lymphoma: does drug exposure really matter?. Leuk Lymphoma 2011; 52:1825-7.
Jun 10, 2011High-dose methotrexate in patients with primary central nervous system lymphoma: does drug exposure really matter?
Jun 10, 2011Leuk Lymphoma 2011; 52:1825-7
Jörger Markus, Huitema A D R, Illerhaus G, Ferreri A J M
Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine
Jörger M, Beijnen J, Huitema A, Rosing H, Vainchtein L, Jansen R, Smits P, Doodeman V, Baas P, Burgers J, Schellens J. Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine. Cancer Chemother Pharmacol 2011; 69:25-33.
May 18, 2011Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine
May 18, 2011Cancer Chemother Pharmacol 2011; 69:25-33
Jörger Markus, Beijnen J H, Huitema A D R, Rosing H, Vainchtein L D, Jansen R S, Smits P H M, Doodeman V D, Baas P, Burgers J A, Schellens J H M
Tubulin, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy
Jörger M, deJong D, Burylo A, Burgers J, Baas P, Huitema A, Beijnen J, Schellens J. Tubulin, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy. Lung Cancer 2011; 74:310-7.
Apr 29, 2011Tubulin, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy
Apr 29, 2011Lung Cancer 2011; 74:310-7
Jörger Markus, deJong D, Burylo A, Burgers J A, Baas P, Huitema A D R, Beijnen J H, Schellens J H M
Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial
Jörger M, Huitema A, Krähenbühl S, Schellens J, Cerny T, Reni M, Zucca E, Cavalli F, Ferreri A. Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial. Br J Cancer 2010; 102:673-7.
Feb 2, 2010Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial
Feb 2, 2010Br J Cancer 2010; 102:673-7
Jörger Markus, Huitema A D R, Krähenbühl S, Schellens J H M, Cerny Thomas, Reni M, Zucca E, Cavalli F, Ferreri A J M
Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic study
Jörger M, Huitema A, Huizing M, Willemse P, de Graeff A, Rosing H, Schellens J, Beijnen J, Vermorken J. Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic study. British journal of clinical pharmacology 2007; 64:622-33.
Nov 1, 2007Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic study
Nov 1, 2007British journal of clinical pharmacology 2007; 64:622-33
Jörger Markus, Huitema A D R, Huizing M T, Willemse P H B, de Graeff A, Rosing H, Schellens J H M, Beijnen J H, Vermorken J B
Interactions of serum albumin, valproic acid and carbamazepine with the pharmacokinetics of phenytoin in cancer patients
Jörger M, Huitema A, Boogerd W, van der Sande J, Schellens J, Beijnen J. Interactions of serum albumin, valproic acid and carbamazepine with the pharmacokinetics of phenytoin in cancer patients. Basic & clinical pharmacology & toxicology 2006; 99:133-40.
Aug 1, 2006Interactions of serum albumin, valproic acid and carbamazepine with the pharmacokinetics of phenytoin in cancer patients
Aug 1, 2006Basic & clinical pharmacology & toxicology 2006; 99:133-40
Jörger Markus, Huitema A D R, Boogerd W, van der Sande J J, Schellens J H M, Beijnen J H
Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients
Jörger M, Huitema A, van den Bongard H, Baas P, Schornagel J, Schellens J, Beijnen J. Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients. British journal of clinical pharmacology 2006; 62:71-80.
Jul 1, 2006Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients
Jul 1, 2006British journal of clinical pharmacology 2006; 62:71-80
Jörger Markus, Huitema A D R, van den Bongard H J G D, Baas P, Schornagel J H, Schellens J H M, Beijnen J H
Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma
Jörger M, Huitema A, Meenhorst P, Schellens J, Beijnen J. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma. Cancer chemotherapy and pharmacology 2005; 55:488-96.
May 1, 2005Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma
May 1, 2005Cancer chemotherapy and pharmacology 2005; 55:488-96
Jörger Markus, Huitema A D R, Meenhorst P L, Schellens J H M, Beijnen J H